A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
NCT05409482 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2025-05-13
Summary
To evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the treatment of unresectable hepatocellular carcinoma.
Conditions
Sponsors & Collaborators
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
collaborator INDUSTRY -
Meng Chao Hepatobiliary Hospital of Fujian Medical University
lead OTHER
Principal Investigators
-
Wu h Guo · Mengchao Hepatobiliary Hospital, Fujian Medical University
-
Zhi bo Zhang · First Affiliated Hospital of Fujian Medical University
-
Yi p Chen · First Affiliated Hospital of Fujian Medical University
-
Ning Huang · Union Hospital Affiliated to Fujian Medical University
-
Mao l Yan · Fujian Provincial Hospital
-
Zhu t Fang · Fujian Provincial Hospital
-
Hui Zhang · Fujian Cancer Hospital
-
Xiao j Zhang · The 900th Hospital of the Joint Logistics Support Force
-
Ling q Yan · Fuqing City Hospital
-
Yan m Zhou · The First Affiliated Hospital of Xiamen University
-
Yong yi Zeng · Mengchao Hepatobiliary Hospital, Fujian Medical University
-
Ping g Liu · Zhongshan Hospital Affiliated to Xiamen University
-
Fu q Wang · Xiamen Hospital of Traditional Chinese Medicine
-
Bo h Zhang · Zhongshan Hospital (Xiamen), Fudan University
-
Cong r Wang · Quanzhou First Hospital
-
Wei Wang · The Second Affiliated Hospital of Fujian Medical University
-
Yu f Chen · Zhangzhou Hospital
-
Shao w Zhuang · Zhangzhou Hospital
-
Jian f Zhao · Affiliated Hospital of Putian University
-
Jia f Chen · Putian First Hospital
-
Wen l Zeng · Longyan Second Hospital
-
Yong z Wang · Sanming Second Hospital
-
Wen f Wu · Nanping Second Hospital
-
Wen x Xie · Fuding City Hospital
-
Feng Lin · Ningde Mindong Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-08-20
- Primary Completion
- 2026-03-01
- Completion
- 2026-03-01
Countries
- China
Study Locations
More Related Trials
-
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
NCT04850040 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT04985136 ·Status: TERMINATED ·Phase: PHASE3
-
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
NCT05412589 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
NCT06546280 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
NCT04930315 ·Status: UNKNOWN ·Phase: PHASE2
-
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
NCT04701060 ·Status: COMPLETED ·Phase: PHASE2
-
Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
NCT04454905 ·Status: UNKNOWN ·Phase: PHASE2
-
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
NCT05613478 ·Status: RECRUITING ·Phase: PHASE3
-
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
NCT05062837 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT05924997 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
NCT05171309 ·Status: UNKNOWN ·Phase: PHASE2
-
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
NCT07154082 ·Status: RECRUITING ·Phase: PHASE2
-
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
NCT05198609 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification
NCT05313282 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
NCT04035876 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
NCT07267806 ·Status: RECRUITING ·Phase: PHASE3
-
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
NCT07314372 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
NCT06280105 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT05367687 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT04639180 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
NCT06739317 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma
NCT04724226 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
NCT06363825 ·Status: RECRUITING ·Phase: PHASE2
-
Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
NCT04806243 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
NCT05742750 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2